Portage Biotech Inc. (PRTG) is an Oil & Gas Production company listed on NASDAQ. There were no new wire items for PRTG in the last 30 days. The most recent was published Sep 5, 2025.
Latest news
25 items- SECSEC Form 424B3 filed by Portage Biotech Inc.424B3 - AlphaTON Capital Corp (0001095435) (Filer)
- SECSEC Form 6-K filed by Portage Biotech Inc.6-K - AlphaTON Capital Corp (0001095435) (Filer)
- SECSEC Form 424B5 filed by Portage Biotech Inc.424B5 - AlphaTON Capital Corp (0001095435) (Filer)
- SECSEC Form 424B3 filed by Portage Biotech Inc.424B3 - AlphaTON Capital Corp (0001095435) (Filer)
- SECSEC Form 6-K filed by Portage Biotech Inc.6-K - PORTAGE BIOTECH INC. (0001095435) (Filer)
- PRAlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram EcosystemDOVER, DE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Unlocks Public Market Access to Toncoin (TON) and Telegram's Billion-User EcosystemBrittany Kaiser, pioneer in data protection, digital assets, and the public equity markets appointed Chief Executive Officer and Board MemberFormerly Portage Biotech Inc. (NASDAQ:PRTG), renamed AlphaTON Capital Corp with new ticker symbol "ATON" effective as of the opening of the market on September 4, 2025 AlphaTON Capital Corp. ("AlphaTON Capital" or the "Company", formerly Portage Biotech Inc.) (NASDAQ:PRTG, ATON)), today announced a financing to acquire ~$100 million TON tokens and establish a specialized digital asset treasury company dedic
- SECSEC Form S-8 filed by Portage Biotech Inc.S-8 - PORTAGE BIOTECH INC. (0001095435) (Filer)
- SECSEC Form 424B3 filed by Portage Biotech Inc.424B3 - PORTAGE BIOTECH INC. (0001095435) (Filer)
- SECSEC Form 424B3 filed by Portage Biotech Inc.424B3 - PORTAGE BIOTECH INC. (0001095435) (Filer)
- SECSEC Form 6-K filed by Portage Biotech Inc.6-K - PORTAGE BIOTECH INC. (0001095435) (Filer)
- SECSEC Form 20-F filed by Portage Biotech Inc.20-F - PORTAGE BIOTECH INC. (0001095435) (Filer)
- PRPortage Biotech Reports Results for Fiscal Year Ended March 31, 2025DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands, with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today reported its financial results for the fiscal year ended March 31, 2025. Financial Results from Year Ended March 31, 2025 The Company incurred a net loss of approximately $6.8 million during the fiscal year ended March 31, 2025 ("Fiscal 2025"), which includes approximately $0.2 million of net non-cash expenses. This compares to a net loss of approximately $75.4 million during the fiscal
- SECSEC Form 424B3 filed by Portage Biotech Inc.424B3 - PORTAGE BIOTECH INC. (0001095435) (Filer)
- SECSEC Form 6-K filed by Portage Biotech Inc.6-K - PORTAGE BIOTECH INC. (0001095435) (Filer)
- SECSEC Form 424B5 filed by Portage Biotech Inc.424B5 - PORTAGE BIOTECH INC. (0001095435) (Filer)
- SECSEC Form 424B3 filed by Portage Biotech Inc.424B3 - PORTAGE BIOTECH INC. (0001095435) (Filer)
- SECSEC Form 6-K filed by Portage Biotech Inc.6-K - PORTAGE BIOTECH INC. (0001095435) (Filer)
- PRPortage Biotech Regains Full Compliance with Nasdaq Continued Listing RequirementsDOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands ("Portage"), announced today that on June 24, 2025, the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. About Portage BiotechPortage Biotech is a clinical-stage immuno-oncology company advancing a pipeline of novel biologics to transform the immune system's ability to fight cancer. For more information, visit www.portagebiotech.com. Forward-Looki
- SECSEC Form 424B3 filed by Portage Biotech Inc.424B3 - PORTAGE BIOTECH INC. (0001095435) (Filer)
- SECSEC Form 6-K filed by Portage Biotech Inc.6-K - PORTAGE BIOTECH INC. (0001095435) (Filer)
- PRPortage Biotech and Compedica Stock-for-Stock ExchangeDOVER, Del., June 09, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands ("Portage") announce that on June 5, 2025 Portage and Compedica Holdings Limited, a company formed under the laws of the Isle of Man ("Compedica") entered a mutual Subscription Agreement ("Subscription Agreement"). Pursuant to the Subscription Agreement, Portage issued 625,000 ordinary shares at a per share price of $8.00 in exchange for 1,165,501 shares of Compedica with a value of $4.29 per share, in a transaction valued at $5,000,000. After the transaction, Compedica will own 27.4% of the issued and outstanding o
- SECSEC Form 424B3 filed by Portage Biotech Inc.424B3 - PORTAGE BIOTECH INC. (0001095435) (Filer)
- SECSEC Form 6-K filed by Portage Biotech Inc.6-K - PORTAGE BIOTECH INC. (0001095435) (Filer)
- SECSEC Form EFFECT filed by Portage Biotech Inc.EFFECT - PORTAGE BIOTECH INC. (0001095435) (Filer)
- SECAmendment: SEC Form F-3/A filed by Portage Biotech Inc.F-3/A - PORTAGE BIOTECH INC. (0001095435) (Filer)
PRTG FAQ
7 questionsWhat does Portage Biotech Inc. do?
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore...What is the latest news on PRTG?
Quantisnow has not tracked any new filings, ratings or press releases for PRTG in the last 30 days. The most recent wire item was published on September 5, 2025.Where does PRTG stock trade?
Portage Biotech Inc. (PRTG) is listed on NASDAQ.What sector and industry is PRTG in?
Portage Biotech Inc. operates in the Energy sector, Oil & Gas Production industry.What are analysts saying about PRTG?
Portage Biotech Inc. has had 5 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $26.00 price target on 2022-07-18. Recent price targets range from $26.00 to $40.00.What companies are similar to PRTG?
Notable peers in the same industry include OXY (Occidental Petroleum Corporation), TTE (TotalEnergies SE), EOG (EOG Resources Inc.), CNQ (Canadian Natural Resources Limited), SHEL (Shell PLC). Compare PRTG side-by-side with any of them on Quantisnow.How can I track PRTG on Quantisnow?
Quantisnow aggregates Portage Biotech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRTG to receive live email and push alerts on every new disclosure.